CDC73 and malignant tumor of parathyroid gland: The absence of parafibromin staining might be an adjunct immunohistochemical marker in the clinical routine for distinguishing benign from malignant parathyroid tumors, predicting the clinical outcome and mortality rate even better than CDC73 mutation [51,52,53].